Veterinary Vaccines

Chapter
Part of the Advances in Delivery Science and Technology book series (ADST)

Abstract

The technology of controlled release has always been attractive to ­veterinary vaccine developers as it has potential to bring a level of convenience, efficacy, and compliance to the use of vaccines. The ability to have in a single therapy or device all that it is required to sensitize and protect an animal may deliver access to new markets, provide differentiation to existing products, and solve ­hitherto unmet needs in veterinary immunology. However, few controlled release vaccine formulations are available at this time despite the sophistication of the materials and devices used for controlled release of medical and veterinary therapeutics. Recent advances in our understanding of how the immune system is sensitized is beginning to allow us to apply new and old technology of controlled release to vaccines across a number of livestock and companion animal species. The technology allows us to control how antigen and adjuvant are presented to the host with increasing fidelity resulting in appropriate levels and duration of immunity. The discovery that many adjuvants work by stimulating the innate immune system has led to the development of molecular adjuvants, which are well suited to devices and controlled release formulations. As controlled release vaccine formulations near late development there are regulatory concerns that need to be addressed as familiar and unfamiliar vaccine components are presented to regulators in a persistent form.

Keywords

Toxicity Hepatitis Chitosan Ethylene Glycol Diesel 

References

  1. 1.
    Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305PubMedCrossRefGoogle Scholar
  2. 2.
    Schijns VE (2002) Antigen delivery systems and immunostimulation. Vet Immunol Immunopathol 87:195–198PubMedCrossRefGoogle Scholar
  3. 3.
    Zinkernagel RM (2003) On natural and artificial vaccinations. Ann Rev Immunol 21:515–546CrossRefGoogle Scholar
  4. 4.
    Medzhitov R, Shevach EM, Trinchieri G, Mellor AL, Munn DH, Gordon S, Libby P, Hansson GK, Shortman K, Dong C, Gabrilovich D, Gabryšová L, Howes A, O’Garra A (2011) Highlights of 10 years of immunology in nature reviews immunology. Nat Rev Immunol 11:693–702PubMedCrossRefGoogle Scholar
  5. 5.
    Meeusen ENT, Walker J, Peters A, Pastoret P, Jungersen G (2007) Current status of veterinary vaccines. Clin Microbiol Rev 20:489–510PubMedCrossRefGoogle Scholar
  6. 6.
    Brown AT, Gregory AR, Ellis TM, Hearnden MN (1999) Comparative immunogenicity of two bivalent botulinum vaccines. Aust Vet J 77:388–391PubMedCrossRefGoogle Scholar
  7. 7.
    Powell MF (1996) Drug delivery issues in vaccine development. Pharm Res 13:1777–1785PubMedCrossRefGoogle Scholar
  8. 8.
    Bishop GA, Hostager BS (2001) B lymphocyte activation by contact-mediated interactions with T lymphocytes. Curr Opin Immunol 13:278–285PubMedCrossRefGoogle Scholar
  9. 9.
    McHeyzer-Williams MG (2003) B cells as effectors. Curr Opin Immunol 15:354–361PubMedCrossRefGoogle Scholar
  10. 10.
    Uzal FA, Bodero DA, Kelly WR, Nielsen K (1998) Variability of serum antibody responses of goat kids to a commercial Clostridium perfringens epsilon toxoid vaccine. Vet Rec 143:472–474PubMedCrossRefGoogle Scholar
  11. 11.
    Mitchison NA (1965) Induction of immunological paralysis in two zones of dosage. Proc R Soc London-B 161:275–292CrossRefGoogle Scholar
  12. 12.
    Nossal GJ, Karvelas M, Pulendran B (1993) Soluble antigen profoundly reduces memory B-cell numbers even when given after challenge immunization. Proc Natl Acad Sci U S A 90:3088–3092PubMedCrossRefGoogle Scholar
  13. 13.
    Kemp JM, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S (2002) Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine 20:1089–1098PubMedCrossRefGoogle Scholar
  14. 14.
    Hanes J, Cleland JL, Langer R (1997) New advances in microsphere-based single-dose vaccines. Adv Drug Deliver Rev 28:97–119CrossRefGoogle Scholar
  15. 15.
    Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, Eastman DJ, Vennari JC, Wrin T, Berman P, Murthy KK, Powell MF (1998) Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. J Pharm Sci 87:1489–1495PubMedCrossRefGoogle Scholar
  16. 16.
    Cleland JL (1999) Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol 17:25–29PubMedCrossRefGoogle Scholar
  17. 17.
    Zinkernagel RM (2000) Localization dose and time of antigens determine immune reactivity. Semin Immunol 12:163–171PubMedCrossRefGoogle Scholar
  18. 18.
    Lofthouse S (2002) Immunological aspects of controlled antigen delivery. Adv Drug Deliv Rev 54:863–870PubMedCrossRefGoogle Scholar
  19. 19.
    Walduck AK, Opdebeeck JP, Benson HE, Prankerd R (1998) Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep. J Control Release 51:269–280PubMedCrossRefGoogle Scholar
  20. 20.
    Sanchez A, Gupta RK, Alonso MJ, Siber GR, Langer R (1996) Pulsed controlled-release system for potential use in vaccine delivery. Pharm Sci 85:547–552CrossRefGoogle Scholar
  21. 21.
    Hughes HP, Campos M, van Drunen Littel-van den Hurk S, Zamb T, Sordillo LM, Godson D, Babiuk LA (1992) Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV. Vaccine 10:226–230PubMedCrossRefGoogle Scholar
  22. 22.
    Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042–1049PubMedCrossRefGoogle Scholar
  23. 23.
    Lafferty KJ, Cunningham AJ (1975) A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 53:27–42PubMedCrossRefGoogle Scholar
  24. 24.
    Medzhitov R, Janeway CA (1996) On the semantics of immune recognition. Res Immunol 147:208–214PubMedCrossRefGoogle Scholar
  25. 25.
    De Veer M, Meeusen E (2011) New developments in vaccine research - unveiling the secret of vaccine adjuvants. Discov Med 12:195–204PubMedGoogle Scholar
  26. 26.
    Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 20:709–760CrossRefGoogle Scholar
  27. 27.
    Diwan M, Tafaghodi M, Samuel J (2002) Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 85:247–262PubMedCrossRefGoogle Scholar
  28. 28.
    Krishnamachari Y, Salem AK (2009) Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 61:205–217PubMedCrossRefGoogle Scholar
  29. 29.
    Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787–796PubMedCrossRefGoogle Scholar
  30. 30.
    De Veer M, Kemp J, Chatelier J, Elhay MJ, Meeusen EN (2010) The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. Vaccine 28:6597–6602PubMedCrossRefGoogle Scholar
  31. 31.
    Cyster JG (2010) B cell follicles and antigen encounters of the third kind. Nat Immunol 11:989–996PubMedCrossRefGoogle Scholar
  32. 32.
    Hem SL, HogenEsch H (2007) Relationship between physical and chemical properties of aluminium-containing adjuvants and immunopotentiation. Expert Rev Vaccines 6:685–698PubMedCrossRefGoogle Scholar
  33. 33.
    Van Nierop K, de Groot C (2002) Human follicular dendritic cells: function, origin and development. Semin Immunol 14:251–257PubMedCrossRefGoogle Scholar
  34. 34.
    Carragher DM, Rangel-Moreno J, Randall TD (2008) Ectopic lymphoid tissues and local immunity. Semin Immunol 20:26–42PubMedCrossRefGoogle Scholar
  35. 35.
    Aguado MT (1993) Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 11:596–597PubMedCrossRefGoogle Scholar
  36. 36.
    Periwal SB, Speaker TJ, Cebra JJ (1997) Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. J Virol 71:2844–2850PubMedGoogle Scholar
  37. 37.
    Siegrist CA (2003) Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21:3406–3412PubMedCrossRefGoogle Scholar
  38. 38.
    Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R (1993) Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 10:945–953PubMedCrossRefGoogle Scholar
  39. 39.
    Chaudhury MR, Sharma K, Giri DK (1996) Poly (d, l-lactide) glycolide polymer microsphere entrapped tetanus toxoid: safety evaluation in Wistar rats. Hum Exp Toxicol 15:205–207PubMedCrossRefGoogle Scholar
  40. 40.
    Higaki M, Azechi Y, Takase T, Igarashi R, Nagahara S, Sano A, Fujioka K, Nakagawa N, Aizawa C, Mizushima Y (2001) Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid. Vaccine 19:3091–3096PubMedCrossRefGoogle Scholar
  41. 41.
    Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A, Vyas S (2005) Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(d, l-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 294:23–32PubMedCrossRefGoogle Scholar
  42. 42.
    Cardamone M, Lofthouse SA, Lucas JC, Lee RP, O’Donoghue M, Brandon MR (1997) In vitro testing of a pulsatile delivery system and its in vivo application for immunisation against tetanus toxoid. J Control Release 47:205–219CrossRefGoogle Scholar
  43. 43.
    Lofthouse S, Nagahara S, Sedgmen B, Barcham G, Brandon M, Sano A (2001) The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep. Vaccine 19:4318–4327PubMedCrossRefGoogle Scholar
  44. 44.
    Lofthouse SA, Kajihara M, Nagahara S, Nash A, Barcham GJ, Sedgmen B, Brandon MR, Sano A (2002) Injectable silicone implants as vaccine delivery vehicles. Vaccine 20:1725–1732PubMedCrossRefGoogle Scholar
  45. 45.
    Kidane A, Guimond P, Ju TR, Sanchez M, Gibson J, Bowersock TL (2001) The efficacy of oral vaccination of mice with alginate encapsulated outer membrane proteins of Pasteurella haemolytica and One-Shot. Vaccine 19:2637–2646PubMedCrossRefGoogle Scholar
  46. 46.
    Mansour M, Brown RG, Morris A (2007) Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model. Clin Vaccine Immunol 14:1381–1383PubMedCrossRefGoogle Scholar
  47. 47.
    Moser CA, Speaker TJ, Offit PA (1997) Effect of microencapsulation on immunogenicity of a bovine herpes virus glycoproteinn and inactivated influenza virus in mice. Vaccine 15:1767–1772PubMedCrossRefGoogle Scholar
  48. 48.
    Toussaint JF, Dubois A, Dispas M, Paquet D, Letellier C, Kerkhofs P (2007) Delivery of DNA vaccines by agarose hydrogel implants facilitates genetic immunization in cattle. Vaccine 25:1167–1174PubMedCrossRefGoogle Scholar
  49. 49.
    Liman M, Peiser L, Zimmer G, Pröpsting M, Naim HY, Rautenschlein S (2007) A genetically engineered prime-boost vaccination strategy for oculonasal delivery with poly(D, L-lactic-co-glycolic acid) microparticles against infection of turkeys with avian Metapneumovirus. Vaccine 25:7914–7926PubMedCrossRefGoogle Scholar
  50. 50.
    Turner JW, Liu IK, Flanagan DR, Bynum KS, Rutberg AT (2002) Porcine zona pellucida (PZP) immunocontraception of wild horses (Equus caballus) in Nevada: a 10 year study. Reprod Suppl 60:177–186PubMedGoogle Scholar
  51. 51.
    Turner JW, Rutberg AT, Naugle RE, Kaur MA, Flanagan DR, Bertschinger HJ, Liu IK (2008) Controlled-release components of PZP contraceptive vaccine extend duration of infertility. Wildlife Res 35:555–562CrossRefGoogle Scholar
  52. 52.
    Dunshea FR, Colantoni C, Howard K, McCauley I, Jackson P, Long KA, Lopaticki S, Nugent EA, Simons JA, Walker J, Hennessy DP (2001) Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases growth performance. J Anim Sci 79:2524–2535PubMedGoogle Scholar
  53. 53.
    Elhay M, Newbold A, Britton A, Turley P, Dowsett K, Walker J (2007) Suppression of behavioural and physiological oestrus in the mare by vaccination against GnRH. Aust Vet J 85:39–45PubMedCrossRefGoogle Scholar
  54. 54.
    Earl ER, Waterston MM, Aughey E, Harvey MJ, Matschke C, Colston A, Ferro VA (2006) Evaluation of two GnRH-I based vaccine formulations on the testes function of entire Suffolk cross ram lambs. Vaccine 24:3172–3183PubMedCrossRefGoogle Scholar
  55. 55.
    Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, O’Hagan DT (1997) Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 65:1716–1721PubMedGoogle Scholar
  56. 56.
    Chandrasekaran R, Giri DK, Chaudhury MR (1996) Embryotoxicity and teratogenicity studies of poly (DL-lactide-co-glycolide) microspheres incorporated tetanus toxoid in Wistar rats. Hum Exp Toxicol 15:349–351PubMedCrossRefGoogle Scholar
  57. 57.
    Zhou S, Liao X, Li X et al (2003) Poly-d, l-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems. J Control Release 86:195–205PubMedCrossRefGoogle Scholar
  58. 58.
    Kang ML, Cho CS, Yoo HS (2009) Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol Adv 27:857–865PubMedCrossRefGoogle Scholar
  59. 59.
    Oh EJ, Park K, Kim KS, Jiseok K, Yang J-A, J-Ha K, Lee MY, Hoffman AS, Hahn SK (2010) Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 141:2–12PubMedCrossRefGoogle Scholar
  60. 60.
    Keppeler S, Ellis A, Jacquier JC (2009) Cross-linked carrageenan beads for controlled release delivery systems. Carbohyd Polym 78:973–977CrossRefGoogle Scholar
  61. 61.
    Bowersock TL, Narishetty S (2009) Vaccine delivery. In: Morishita M, Park K (eds) Biodrug delivery systems, fundamentals applications, and clinical development. Informa Healthcare, New York, pp 412–424Google Scholar
  62. 62.
    Bowersock TL, Martin S (1999) Vaccine delivery to animals. Adv Drug Deliver Rev 38:167–194CrossRefGoogle Scholar
  63. 63.
    Aucouturier J, Dupuis L, Ganne V (2001) Adjuvants designed for veterinary and human vaccines. Vaccine 19:2666–2672PubMedCrossRefGoogle Scholar
  64. 64.
    Mutoloki S, Alexandersen S, Gravningen K, Evensen O (2008) Time-course study of injection site inflammatory reactions following intraperitoneal injection of Atlantic cod (Gadus morhua L.) with oil-adjuvanted vaccines. Fish Shellfish Immunol 24:386–393PubMedCrossRefGoogle Scholar
  65. 65.
    Pilström L (2005) Adaptive immunity in teleosts: humoral immunity. In: Midtlyng PJ (ed) Progress in fish vaccinology. Karger, Switzerland, p 23Google Scholar
  66. 66.
    Anderson DP (1997) Adjuvants and immunostimulants for enhancing vaccine potency in fish. Dev Biol Stand 90:257–265PubMedGoogle Scholar
  67. 67.
    MacDonald LD, Fuentes-Ortega A, Sammatur L (2010) Efficacy of a single dose hepatitis B depot vaccine. Vaccine 28:7143–7145PubMedCrossRefGoogle Scholar
  68. 68.
    Karkada M, Weir GM, Quinton T, Fuentes-Ortega A, Mansour M (2010) A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine 28:6176–6182PubMedCrossRefGoogle Scholar
  69. 69.
    Medlicott NJ, Tucker IG (1999) Pulsatile release from subcutaneous implants. Adv Drug Deliver Rev 38:139–149CrossRefGoogle Scholar
  70. 70.
    Sullivan MM, Vanoverbeke DL, Kinman LA, Krehbiel CR, Hilton GG, Morgan JB (2009) Comparison of the Biobullet versus traditional pharmaceutical injection techniques on injection-site tissue damage and tenderness in beef subprimals. J Anim Sci 87:716–722PubMedCrossRefGoogle Scholar
  71. 71.
    Bowersock TL, HogenEsch H, Torregrosa S, Borie D, Wang B, Park H, Park K (1998) Induction of pulmonary immunity in cattle by oral administration of ovalbumin in alginate microspheres. Immunol Lett 60:37–43PubMedCrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2013

Authors and Affiliations

  1. 1.Veterinary Medicines R&D, Pfizer Animal HealthParkvilleAustralia

Personalised recommendations